bfcr4350a
mAbexperimentalMulti-specific
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 19, 2017 (NCT03275103)
Timeline
Indications
Studied for
Mechanism of action
- Fc receptor-like protein 5INHIBITOR
FCRL5 inhibitor
CD3E inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297908 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06934044 | Phase 1 | May 13, 2025 | Roche |
| NCT05927571 | Phase 1 | Aug 9, 2023 | Genentech, Roche |
| NCT05801939 | Phase 2 | Jul 11, 2023 | Genentech, University of Pennsylvania |
| NCT05646836 | Phase 1 | Jan 3, 2023 | Genentech, Roche |
| NCT05583617 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | Roche |
| NCT05535244 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2022 | Roche |
| NCT04910568 | Phase 1 | Jul 26, 2021 | Genentech, Roche |
| NCT03275103 | Phase 1 | Sep 19, 2017 | Genentech |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 6 | 3 | 2 | 2021 |
| Genentech | For profit | 5 | 4 | 2 | 2017 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1